FZD5 prevents epithelial-mesenchymal transition in gastric cancer

被引:23
|
作者
Dong, Dan [1 ]
Na, Lei [1 ,2 ]
Zhou, Kailing [1 ]
Wang, Zhuo [1 ]
Sun, Yu [1 ]
Zheng, Qianqian [1 ]
Gao, Jian [3 ]
Zhao, Chenghai [1 ]
Wang, Wei [1 ]
机构
[1] China Med Univ, Coll Basic Med Sci, Dept Pathophysiol, Shenyang, Peoples R China
[2] China Med Univ, Shengjing Hosp, Dept Urol, Shenyang, Peoples R China
[3] China Med Univ, Ctr Lab Technol & Expt Med, Shenyang, Peoples R China
基金
中国博士后科学基金;
关键词
FZD5; Epithelial-mesenchymal transition; ELF3; Gastric cancer;
D O I
10.1186/s12964-021-00708-z
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Background: Frizzled (FZD) proteins function as receptors for WNT ligands. Members in FZD family including FZD2, FZD4, FZD7, FZD8 and FZD10 have been demonstrated to mediate cancer cell epithelial-mesenchymal transition (EMT). Methods: CCLE and TCGA databases were interrogated to reveal the association of FZD5 with EMT. EMT was analyzed by investigating the alterations in CDH1 (E-cadherin), VIM (Vimentin) and ZEB1 expression, cell migration and cell morphology. Transcriptional modulation was determined by ChIP in combination with Real-time PCR. Survival was analyzed by Kaplan-Meier method. Results: In contrast to other FZDs, FZD5 was identified to prevent EMT in gastric cancer. FZD5 maintains epithelial-like phenotype and is negatively modulated by transcription factors SNAI2 and TEAD1. Epithelial-specific factor ELF3 is a downstream effecter, and protein kinase C (PKC) links FZD5 to ELF3. ELF3 represses ZEB1 expression, further guarding against EMT. Moreover, FZD5 signaling requires its co-receptor LRP5 and WNT7B is a putative ligand for FZD5. FZD5 and ELF3 are associated with longer survival, whereas SNAI2 and TEAD1 are associated with shorter survival. Conclusions: Taken together, FZD5-ELF3 signaling blocks EMT, and plays a potential tumor-suppressing role in gastric cancer.
引用
收藏
页数:13
相关论文
共 50 条
  • [41] IGFBP7 promotes gastric cancer by facilitating epithelial-mesenchymal transition of gastric cells
    Wang, Jinqing
    Wang, Xinxin
    Liu, Zhaorui
    Li, Sheng
    Yin, Wenbin
    HELIYON, 2024, 10 (10)
  • [42] Epithelial-Mesenchymal Transition
    Zavadil, Jiri
    Haley, John
    Kalluri, Raghu
    Muthuswamy, Senthil K.
    Thompson, Erik
    CANCER RESEARCH, 2008, 68 (23) : 9574 - 9577
  • [43] Epithelial-mesenchymal transition
    Kubik, Joanna
    Pawlak, Kamil
    CURRENT ISSUES IN PHARMACY AND MEDICAL SCIENCES, 2023, 36 (01) : 18 - 20
  • [44] Epithelial-Mesenchymal Transition in Cancer of Unknown Primary
    Stoyianni, A.
    Goussia, A.
    Pentheroudakis, G.
    Siozopoulou, V.
    Cervantes, A.
    Bobos, M.
    Fountzilass, G.
    Malamou-Mitsi, V.
    Pavlidis, N.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S133 - S133
  • [45] Quantitate epithelial-mesenchymal transition in ovarian cancer
    Tan, Tuan Zea
    Huang, Ruby Yun-Ju
    Miow, Qing Hao
    Ye, Jieru
    Wong, Meng Kang
    Lau, Jieying Amelia
    Mori, Seiichi
    Thiery, Jean Paul
    CLINICAL CANCER RESEARCH, 2015, 21
  • [46] Epithelial-mesenchymal transition in cancer of unknown primary
    Siozopoulou, V.
    Goussia, A.
    Stoyianni, A.
    Pentheroudakis, G.
    Nesseris, I.
    Oikonomou, P.
    Papoudou-Bai, A.
    Pavlidis, N.
    Malamou-Mitsi, V.
    VIRCHOWS ARCHIV, 2011, 459 : S212 - S212
  • [47] Epithelial-mesenchymal transition
    Radisky, DC
    JOURNAL OF CELL SCIENCE, 2005, 118 (19) : 4325 - 4326
  • [48] Exosomes Regulate the Epithelial-Mesenchymal Transition in Cancer
    Jiang, Jingwen
    Li, Jiayu
    Zhou, Xiumei
    Zhao, Xueqin
    Huang, Biao
    Qin, Yuan
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [49] Mechanism and regulation of epithelial-mesenchymal transition in cancer
    Reed, Irene K. Guttilla
    CELL HEALTH AND CYTOSKELETON, 2015, 7 : 155 - 165
  • [50] Epithelial-Mesenchymal Transition in Cancer: A Historical Overview
    Ribatti, Domenico
    Tamma, Roberto
    Annese, Tiziana
    TRANSLATIONAL ONCOLOGY, 2020, 13 (06):